【2h】

Oxymetholone in aplastic anaemia

机译:羟甲羟喹在再生障碍性贫血中

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Thirty-one patients with aplastic anaemia were treated with oxymetholone. Twenty-eight patients lived beyond 2 months and of these eleven patients showed clinical and haematological improvement. Ten of these had some active erythropoietic areas as shown by bone marrow biopsies and by the presence of an elevated reticulocyte count in the peripheral blood. Two patients who responded in spite of a markedly hypoplastic marrow and reticulocytopenia became oxymetholone dependent and relapsed when the drug was withdrawn. They failed to respond a second time when oxymetholone was re-introduced. Side effects were frequent. These were mostly tolerable and reversible on reduction of the dose but three patients died of acute myeloblastic leukaemia and in three others the drug had to be withdrawn.
机译:31例再生障碍性贫血患者接受了羟甲烯龙治疗。 28名患者的生存期超过2个月,其中11名患者的临床和血液学均有改善。如骨髓活检和外周血中网织红细胞计数升高所示,其中有十个具有活跃的红细胞生成区域。尽管有明显的发育不良的骨髓和网状细胞减少症,但仍然有反应的两名患者成为羟甲羟吗啡酮依赖性药物,并在停药后复发。当再次引入羟甲烯龙时,他们没有第二次做出反应。副作用是频繁的。这些药物在降低剂量后大部分是可以耐受的和可逆的,但是三名患者死于急性粒细胞性白血病,其他三名患者则不得不停药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号